Show simple item record

dc.contributor.authorDenis-Bacelar, AM
dc.contributor.authorChittenden, SJ
dc.contributor.authorMurray, I
dc.contributor.authorDivoli, A
dc.contributor.authorRalph McCready, V
dc.contributor.authorDearnaley, DP
dc.contributor.authorO'Sullivan, JM
dc.contributor.authorJohnson, B
dc.contributor.authorFlux, GD
dc.date.accessioned2017-05-12T15:13:09Z
dc.date.issued2017-04
dc.identifier.citationPhysics in medicine and biology, 2017, 62 (7), pp. 2859 - 2870
dc.identifier.issn0031-9155
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/639
dc.identifier.eissn1361-6560
dc.identifier.doi10.1088/1361-6560/aa5e6f
dc.description.abstractSkeletal tumour burden is a biomarker of prognosis and survival in cancer patients. This study proposes a novel method based on the linear quadratic model to predict the reduction in metastatic tumour burden as a function of the absorbed doses delivered from molecular radiotherapy treatments. The range of absorbed doses necessary to eradicate all the bone lesions and to reduce the metastatic burden was investigated in a cohort of 22 patients with bone metastases from castration-resistant prostate cancer. A metastatic burden reduction curve was generated for each patient, which predicts the reduction in metastatic burden as a function of the patient mean absorbed dose, defined as the mean of all the lesion absorbed doses in any given patient. In the patient cohort studied, the median of the patient mean absorbed dose predicted to reduce the metastatic burden by 50% was 89 Gy (interquartile range: 83-105 Gy), whilst a median of 183 Gy (interquartile range: 107-247 Gy) was found necessary to eradicate all metastases in a given patient. The absorbed dose required to eradicate all the lesions was strongly correlated with the variability of the absorbed doses delivered to multiple lesions in a given patient (r  =  0.98, P  <  0.0001). The metastatic burden reduction curves showed a potential large reduction in metastatic burden for a small increase in absorbed dose in 91% of patients. The results indicate the range of absorbed doses required to potentially obtain a significant survival benefit. The metastatic burden reduction method provides a simple tool that could be used in routine clinical practice for patient selection and to indicate the required administered activity to achieve a predicted patient mean absorbed dose and reduction in metastatic tumour burden.
dc.formatPrint
dc.format.extent2859 - 2870
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectBone Neoplasms
dc.subjectRadiopharmaceuticals
dc.subjectPrognosis
dc.subjectRadiotherapy Dosage
dc.subjectRadiobiology
dc.subjectMale
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.titleA radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases.
dc.typeJournal Article
dcterms.dateAccepted2017-02-06
rioxxterms.versionofrecord10.1088/1361-6560/aa5e6f
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfPhysics in medicine and biology
pubs.issue7
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume62
pubs.embargo.termsNo embargo
icr.researchteamClinical Academic Radiotherapy (Dearnaley)en_US
icr.researchteamRadioisotope Physicsen_US
dc.contributor.icrauthorMurray,en
dc.contributor.icrauthorDearnaley, Daviden
dc.contributor.icrauthorFlux, Glennen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0